Company intelligence / Profile preview

Anrui Biopharmaceutical Technology

Tonghua, Jilin Sheng, Chinamarketscreener.com ↗

Ownership: Private
Development stage: Other

Overview

Tonghua Anrui Biopharmaceuticals is a high-tech biopharma company founded in August 2014, focused on R&D and manufacturing. Its lead product is a national Class I novel drug—recombinant human albumin injection—targeting liver cirrhosis with ascites. The main clinical study aims to evaluate safety, tolerability, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity in this patient population. The company integrates both research and large-scale production capabilities.

Therapeutic areas: GastroenterologyHematology
Modalities: Recombinant proteins, specifically recombinant human albumin injection
Industry: Biotech

Beyond the preview

Go deeper on Anrui Biopharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anrui Biopharmaceutical Technology.

Explore the full profile